Index

Page numbers in *italics* indicate tables and figures.

acculturation, 143, 146, 149, 161
acute-phase response, 41, 42–43
ADVANCE trial, 117–118
adversity, childhood, 38, 43, 48–49
African Americans, 5, 65, 150–151, 155

age
  and cognitive dysfunction, 118
  and depression, 4, 7, 82, 146–147
  and diabetes, 66, 144, 146–147
Ali, S., 66
alternative therapies, beliefs in, 112
amitriptyline, 122
anakinra, 42
Anderson, R.J., 65, 145
antidepressants
  choice of, 101, 122–124
  and cortisol levels, 37
  diabetes patients, effects on, 49–50
  and gender variations, 7
  and insulin sensitivity, 34
  maintenance trials, 96–97
serotonin syndrome, 122
side effects, 122–123
suicide risk, 122–123
anxiety disorder, 11, 65, 99, 101, 112
Asghar, S., 5, 65
Asian populations, 111, 151–153, 155
autonomic nervous system, 36, 39–41, 42, 47, 51
autonomic neuropathy, 40–41
Baltimore Epidemiological Catchment Area Study, 48
behavioural therapies, 131
birth weight, 46–47
Bjorntorp, P., 36
British Cohort Study, 46–47
British Women’s Heart and Health study, 32
bupropion, 97, 101
cardiovascular disease
  depression as risk factor for, 9, 116
  and heart rate variability (HRV), 39–40
  risk of, in diabetes patients, 115–116
  and socioeconomic status, 148
  and stress, 36
care see collaborative care
childhood adversity, 38, 43, 48–49
Chin, M.H., 151
China, 111, 144, 152–153

see also Asian populations

Ciechanowski, P.S., 68
citalopram, 50
clomipramine, 50
cognitive dysfunction
and age, 118
clinical outcomes, effect on, 117–119
diabetes and depression,
relationship with, 109, 118
diagnosing/evaluating, 113,
120–121
and glycaemic control, 114–115
hyperglycaemia, effect of, 116–117
and insulin resistance, 117
collaborative care
components of, 93
cost savings of, 71, 74, 95–96, 96
effectiveness trials, 93–96
efficacy studies, 83–84, 85–91, 92
improving, 99, 100, 101, 102–103
information sharing, 121
maintenance trials, 96–97
need for, 113–114, 119, 131,
158, 159
Piette treatment model, 97–98, 98
practice setting, changes to, 121
Collins, M.M., 7
coronary artery disease (CAD)
and childhood adversity, 48
and depression, 13, 31, 43, 44–45
and heart rate variability (HRV), 40
and hypercortisolaemia, 37, 38
corticotropin-releasing hormone
(CRH), 35, 36–37
cortisol levels, 35, 36–38, 42, 117, 146
costs, medical, 72–73
of depression, 66–67
of diabetes, 66
of diabetes with comorbid
depression, 68–71, 70, 110,
129, 159

benefits of collaborative care, 71,
74, 95–96, 96, 124
Cox, D.J., 115
C-reactive protein (CRP), 42, 43,
48–49
culture
age, 146–147
barriers, overcoming, 114,
156–157, 160–161
defined, 143
ethnicity, 150, 150–155
gender, 145–146
impact on therapy, 111–112, 113
migration, 149–150
reducing health disparities,
156–160
socioeconomic status, 147–149
Cushing’s syndrome, 36
cytokines, 41–43, 50
depression
chronicity of, in diabetes
patients, 82
comorbid, and mortality, 12, 13
and coronary artery disease, 31
defined, 2
diabetes patients, effects on, 12–15,
67–68, 81–82, 125, 145
and diabetes-related distress,
11–12, 12
diagnosing, 2, 3
link to diabetes, model of, 31
prevalence of, 64
in diabetes patients, 1–5,
65–66, 81
recurrence of, 7–8
relapse prevention, 97
as risk factor
for cardiovascular disease, 9, 116
for diabetes, 8–9, 145
screening for, 99, 102, 119–120,
125–126
self-reporting, 34
symptoms of, 3, 124–125
and vascular disease, 13
see also antidepressants
desipramine, 122
diabetes
control methods, 42
link to depression, model of, 31
prevalence of, 63–64, 143–144
by ethnic group, 150
Diabetes and Depression Initiative, ix
diabetes distress, 11–12, 12, 31
Diabetes Distress Scale (DDS), 125–126
disparities, health, 156–160
dopamine reward system, 45–46
drug interactions, 122, 123
drugs see medication
Druss, B.G., 67
duloxetine, 101
Dunedin Multidisciplinary Health and Development Study, 48
early detection programmes, 158, 159
eating disorders, 11, 45, 101, 127–128
educating patients
about depression, 94, 160
about diabetes, 10, 157–158
about diabetes with comorbid
depression, 93, 99–100, 126, 154–155
educational attainment, 48, 144, 148
Egede, L.E., 69, 129
escitalopram, 50
ethnicity, 150, 150–155
fatalism, 111–112
Finkelstein, E.A., 69
foetal origins hypothesis, 46–47
follow-up care, 131, 157
Garrison, M.M., 75
gastrointestinal-autonomic
neuropathy studies, 40–41
Gendelman, N., 3
gender, 7, 83, 145–146
Generalized Anxiety Disorder
Assessment-7 (GAD-7), 101
genes, inflammatory, 44–45
genetics, 44–46
Gilbody, S., 99
Gilmer, T.P., 69
glycaemic control
antidepressants, effects of, 49, 96–97
and cognitive status/mood,
114–115, 118
depression, effects of, 10, 30
pharmacotherapeutic treatments,
effectiveness of, 92
and quality of life, 147
Gollust, S.E., 158
Harris, T., 38
health disparities, reducing,
156–160
healthcare use, 72–73
depression, 66–67
diabetes, 66
diabetes with comorbid depression,
68–71, 69
patient changes in, 128–129
Heart and Soul Study, 9, 37
heart rate variability (HRV),
39–41
Hispanic Established Population for
the Epidemiologic Study of the Elderly (EPESE), 13–14, 68, 145
Hispanic populations, 5, 65, 68, 112, 153–155, 155
Hsu, L.K., 152
hypercortisolaemia, 35–39, 51
hyperglycaemia, 110, 115, 116–117, 118, 122, 127
hypoglycaemia, 110, 115, 116, 117–118
hypothalamic-pituitary-adrenal (HPA) axis, 35–39, 39, 42, 47, 51, 117, 127

imipramine, 50

immune system, 42

Improving Mood-Promoting Access to Collaborative (IMPACT), 71, 124

India, 144–145

inflammatory markers, measuring, 42–43

inflammatory response, 41–43, 117

insulin resistance, 32, 33, 34–35, 49, 117, 151–152

interleukin (IL), 42–43

international variations, 5, 64

Kalsekar, I.D., 69–70

Katon, W.J., 74

Keita, G.P., 145–146

Kleinman, A., 111

Kovacs, M., 7

language barriers, overcoming, 112–113

Lantz, P.M., 158

Latino populations, 5, 65, 68, 112, 153–155, 155

Le, T.K., 69

Li, C., 65

life course epidemiology, 48–49

Lin, E.H.B., 126

Lustman, P.J., 7, 92, 127

macrophage theory, 41–42

maintenance antidepressant trials, 96–97

mass media, use of, 158

Medical Expenditure Panel Survey (MEPS), 70–71

medication

amitriptyline, 122

anakinra, 42

antidepressants, 3, 7, 49–50, 96–97, 122–124

buproprion, 97, 101

citalopram, 50

clomipramine, 50

desipramine, 122

drug interactions, 122, 123

duloxetine, 101

escitalopram, 50

imipramine, 50

metformin, 50

monoamine oxidase inhibitors, 49, 122

nortriptyline, 7, 122

paroxetine, 50, 123

reviewing, 124

serotonin reuptake inhibitors (SSRIs), 49, 92, 96–97, 101, 122–123

serotonin-noradrenaline reuptake inhibitors (SNRIs), 50, 101

sertraline, 96–97

sibutramine, 49–50

side effects, 122–124

St. John’s wort, 123

tricyclic antidepressants, 34, 49

venlafaxine, 101

mental health care, 82–83

metabolic syndrome, 9, 36

metformin, 50

Mezuk, B., 8–9

migration, 149–150

monoamine oxidase inhibitors, 49, 122

mood disorders, 64, 65

morbidity, 64, 115–116

Morse, S., 128

mortality, 13–14, 14, 15, 31, 63–64, 115–116, 145

National Health and Nutrition Examination Study (NHANES), 14
Native Americans, 5, 111, 113
nervous system, 36, 39–41, 42, 47, 51
Netherlands Study of Depression and Anxiety, 37–38
Nichols, L., 70
night eating syndrome, 101, 128
nortriptyline, 7, 122
nurses, 102, 103, 122, 124, 158, 159, 161

obesity, 9, 32, 36, 42, 45, 49–50

Parker, G., 152
paroxetine, 50, 123
Pathways Study, 13, 74, 124
Patient Health Questionnaire-9 (PHQ-9), 2, 93, 99, 102, 103, 125

patients
care of see collaborative care
educating, 99, 101, 116, 126, 157
emotional distress of, 113
failure to continue medication, 122
follow-up care, 131, 157
frustration/demoralization of, 99, 125
optimizing relationship with, 125–128, 129–130
self-care see self-care for glycaemic control
understanding/respecting, 99
peer support, 156, 158–159
pharmacological treatments, 51
efficacy studies, 84, 88–91, 92
see also antidepressants; medication
physical inactivity, 9, 32, 150
Piette, J.D., 97–98
Piette treatment model, 97–98, 98
prevention strategies, 161
primary care systems, improving, 102–103, 121, 156–160
see also collaborative care

Prospect Trial, 124
psychological disorders, 10–12, 12
psychotherapeutic treatments, 84, 85–88, 92
registries, use of, 103, 158
relapse prevention, 97
research, future
depression-HRV link, 41
healthcare use/cost, 74–75
national/cultural variations, 5, 16
pharmacological, 51
type 1 and type 2 differences, 74
risk factors
for cardiac disease, 39
for cardiovascular disease, 9, 82, 149
for comorbid depression, 6, 6–7, 8, 48–49, 118, 145, 147
for depression, 4, 6, 6, 45
for diabetes, 8–9, 153–154
Sartorius, N., 111
self-care for glycaemic control, 9–10
burden of, 4
cognitive dysfunction, effects of, 116
depression, effects of, 10, 12, 126–127
and diabetes distress, 31
hypo/hyperglycaemia, effects of, 115
improving, 92
self-harm, 122
serotonin reuptake inhibitors (SSRIs), 49, 92, 96–97, 101, 122–123
serotonin syndrome, 122
serotonin-noradrenaline reuptake inhibitors (SNRIs), 50, 101
sertraline, 96–97
sibutramine, 49–50
Simon, G.E., 70, 74
Skodova, Z., 148

INDEX 179
smoking, 128
social stigmatization, 13, 111, 114, 151, 152–153
socioeconomic status, 6, 16, 48, 147–149
Sotiropoulos, A., 65
Southampton Women’s Survey Study, 47
St. John’s wort, 123
stepped care, 93–94
stress
  and acute-phase response, 42–43
  and age, 146
  anxiety disorders, 11, 65, 99, 101, 112
  and cardiovascular disease, 36
  and C-reactive protein (CRP), 43
  and depression recurrence, 7–8
  and gender, 145
  and HPA axis response, 35–39, 42, 47, 51, 117, 127
  and migration, 149–150
  and socioeconomic status, 148
  see also diabetes distress
Study of Women’s Health Across the Nation, 34–35
suicide, 122–123
survival functions, 14, 15
susto, 112, 154
sympathetic nervous system (SNS), 36, 39–41, 42, 47, 51
TEAMcare trial, 103
tobacco use, 128
treatment see collaborative care
tricyclic antidepressants, 34, 49
tumor necrosis factor (TNF)-α, 42, 43
Unutzer, J., 67
urbanization, 144, 149–150
vascular disease, 13
  see also cardiovascular disease
venlafaxine, 101
Willis, Thomas, ix, 9
World Mental Health Survey, 65
Zahid, N., 65
Zhang, X., 14